专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20200332373A1 Compositions And Methods For Determining Resistance To Inhibitors Of Virus Entry Using Recombinant Virus Assays 审中-公开
公开(公告)号：US20200332373A1
公开(公告)日：2020-10-22
申请号：US16780426
申请日：2020-02-03
申请人： MONOGRAM BIOSCIENCES, INC.
发明人： Christos J. Petropoulos
IPC分类号： C12Q1/70 , C12N7/00 , C12Q1/66 , C07K14/005 , C12Q1/04 , G01N33/50
摘要： The invention provides a method for determining whether a human immunodeficiency virus is resistant to a viral entry inhibitor. The methods are particularly useful for determining resistance to inhibitors that act by a non-competitive mechanism. In certain aspects, the methods comprise determining whether an HIV population is resistant to an HIV entry inhibitor, comprising determining a log-sigmoid inhibition curve comprising data points for entry of the HIV population in the presence of varying concentrations of the HIV entry inhibitor, wherein if the entry of the HIV population cannot be completely inhibited by the HIV entry inhibitor, the HIV population is resistant to the HIV entry inhibitor.

2. 发明授权

US09939447B2 Methods and compositions for analyzing proteins 有权
公开(公告)号：US09939447B2
公开(公告)日：2018-04-10
申请号：US14826573
申请日：2015-08-14
申请人： Monogram Biosciences, Inc.
发明人： Sharat Singh , Hossein Salimi-Moosavi , Syed Hasan Tahir , Gerald J. Wallweber , Hrair Kirakossian , Tracy J. Matray , Vincent S. Hernandez
IPC分类号： G01N33/68 , C07K16/00 , G01N33/58
CPC分类号： G01N33/6842 , C07K16/00 , C07K2317/40 , G01N33/582 , G01N33/6803
摘要： Compositions, kits, and methods are disclosed for determining one or more target polypeptides in a sample where the target polypeptides have undergone a post-translational modification. The compositions can include a first reagent including a cleavage-inducing moiety and a first binding agent for a binding site that includes a post-translational modification of a target polypeptide.

3. 发明申请

US20170067878A1 Molecular Determinants Associated with Enhanced Ability to Enter Cells Expressing CXCR4 审中-公开
标题翻译：与增强表达CXCR4细胞的能力相关的分子决定因素
公开(公告)号：US20170067878A1
公开(公告)日：2017-03-09
申请号：US15348307
申请日：2016-11-10
申请人： Monogram Biosciences, Inc.
发明人： Wei Huang
IPC分类号： G01N33/50 , C12Q1/68 , G01N33/68
CPC分类号： G01N33/5041 , C12N2740/16111 , C12Q1/6897 , C12Q1/703 , G01N33/6863 , G01N2333/162 , G01N2333/7158
摘要： The invention provides a method for determining whether a human immunodeficiency virus is likely to be have enhanced ability to enter a cell expressing CD4 and CXCR4 relative to a reference HIV. In certain aspects, the methods comprise detecting one or more amino acids in an envelope protein of the HIV associated with enhanced ability to enter CD4- and CXCR4-expressing cells and determining that the HIV's ability to enter such cells is enhanced relative to a reference HIV, e.g., an HIV that does not comprise such amino acid(s).
摘要翻译：本发明提供了一种用于确定人类免疫缺陷病毒是否可能相对于参考HIV进一步进入表达CD4和CXCR4的细胞的能力的方法。在某些方面，所述方法包括检测与进入CD4和CXCR4表达细胞的增强能力相关的HIV的包膜蛋白中的一个或多个氨基酸，并确定进入这些细胞的HIV相对于参照HIV的增强能力，例如，不包含这种氨基酸的HIV。

4. 发明申请

US20160069893A1 Methods and Compositions for Analyzing Proteins 有权
标题翻译：分析蛋白质的方法和组成
公开(公告)号：US20160069893A1
公开(公告)日：2016-03-10
申请号：US14826573
申请日：2015-08-14
申请人： Monogram Biosciences, Inc.
发明人： Sharat Singh , Hossein Salimi-Moosavi , Syed Hasan Tahir , Gerald J. Wallweber , Hrair Kirakossian , Tracy J. Matray , Vincent S. Hernandez
IPC分类号： G01N33/68 , C07K16/00 , G01N33/58
CPC分类号： G01N33/6842 , C07K16/00 , C07K2317/40 , G01N33/582 , G01N33/6803
摘要： Methods, compositions and kits are disclosed for determining one or more target polypeptides in a sample where the target polypeptides have undergone a post-translational modification. A mixture comprising the sample and a first reagent comprising a cleavage-inducing moiety and a first binding agent for a binding site on a target polypeptide is subjected to conditions under which binding of respective binding moieties occurs. The binding site is the result of post-translational modification activity involving the target polypeptide. The method may be employed to determine the target polypeptide itself. In another embodiment the presence and/or amount of the target polypeptide is related to the presence and/or amount and/or activity of an agent such as an enzyme involved in the post-translational modification of the target polypeptide. The interaction between the first binding agent and the binding site brings the cleavage-inducing moiety into close proximity to a cleavable moiety, which is associated with the polypeptide and is susceptible to cleavage only when in proximity to the cleavage-inducing moiety. In this way, an electrophoretic tag for each of the polypeptides may be released. Released electrophoretic tags are separated and the presence and/or amount of the target polypeptides are determined based on the corresponding electrophoretic tags.
摘要翻译：公开了用于确定样品中一种或多种靶多肽已经经历了翻译后修饰的方法，组合物和试剂盒。包含样品和包含切割诱导部分的第一试剂和用于靶多肽上的结合位点的第一结合剂的混合物经受各自结合部分的结合发生的条件。结合位点是涉及靶多肽的翻译后修饰活性的结果。该方法可用于确定靶多肽本身。在另一个实施方案中，靶多肽的存在和/或量与试剂例如涉及靶多肽的翻译后修饰的酶的存在和/或量和/或活性有关。第一结合剂和结合位点之间的相互作用使切割诱导部分紧密接近可切割部分，其可与多肽相关，并且仅在接近切割诱导部分时易于切割。以这种方式，可以释放每个多肽的电泳标签。分离释放的电泳标签，并且基于相应的电泳标签确定靶多肽的存在和/或量。

5. 发明申请

US20140272930A1 Compositions And Methods For Determining Resistance To Inhibitors Of Virus Entry Using Recombinant Virus Assays 审中-公开
标题翻译：使用重组病毒测定法确定病毒进入抑制剂的抗性的组合物和方法
公开(公告)号：US20140272930A1
公开(公告)日：2014-09-18
申请号：US14100467
申请日：2013-12-09
申请人： MONOGRAM BIOSCIENCES, INC.
发明人： Christos J. Petropoulos
IPC分类号： C12Q1/70
CPC分类号： C12Q1/703 , C07K14/005 , C12N7/00 , C12N2740/16062 , C12N2740/16122 , C12N2800/107 , C12N2800/40 , C12Q1/04 , C12Q1/66 , G01N33/5008 , G01N2333/16 , G01N2333/162
摘要： The invention provides a method for determining whether a human immunodeficiency virus is resistance to a viral entry inhibitor. The methods are particularly useful for determining resistance to inhibitors that act by a non-competitive mechanism. In certain aspects, the methods comprise determining whether an HIV population is resistant to an HIV entry inhibitor, comprising determining a log-sigmoid inhibition curve comprising data points for entry of the HIV population in the presence of varying concentrations of the HIV entry inhibitor, wherein if the entry of the HIV population cannot be completely inhibited by the HIV entry inhibitor, the HIV population is resistant to the HIV entry inhibitor.
摘要翻译：本发明提供了一种用于确定人类免疫缺陷病毒是否对病毒进入抑制剂的抗性的方法。该方法对于确定通过非竞争性机制起作用的抑制剂的抗性特别有用。在某些方面，所述方法包括确定HIV群体对HIV入侵抑制剂是否具有抗性，包括确定在存在不同浓度的HIV入侵抑制剂的情况下包括HIV群体进入的数据点的对数乙状结肠抑制曲线，其中如果艾滋病毒携带者的输入不能完全被艾滋病毒入侵者抑制，艾滋病毒携带者就能抵抗艾滋病毒入侵者。

6. 发明公开

US20230313327A1 Compositions and Methods for Determining Resistance to Inhibitors of Virus Enter Using Recombinant Virus Assays 审中-公开
公开(公告)号：US20230313327A1
公开(公告)日：2023-10-05
申请号：US17959168
申请日：2022-10-03
申请人： Monogram Biosciences, Inc.
发明人： Christos J. Petropoulos
IPC分类号： C12N7/00 , C07K14/005 , C12Q1/70 , G01N33/50
CPC分类号： C12Q1/703 , C07K14/005 , C12N7/00 , C12Q1/70 , G01N33/5008 , C12N2740/16062 , C12Q1/66 , G01N2333/162
摘要： The invention provides a method for determining whether a human immunodeficiency virus is resistant to a viral entry inhibitor. The methods are particularly useful for determining resistance to inhibitors that act by a non-competitive mechanism. In certain aspects, the methods comprise determining whether an HIV population is resistant to an HIV entry inhibitor, comprising determining a log-sigmoid inhibition curve comprising data points for entry of the HIV population in the presence of varying concentrations of the HIV entry inhibitor, wherein if the entry of the HIV population cannot be completely inhibited by the HIV entry inhibitor, the HIV population is resistant to the HIV entry inhibitor.

7. 发明申请

US20190025305A1 Compositions and Methods for Evaluating Viral Receptor/Co-Receptor Usage and Inhibitors of Virus Entry Using Recombinant Virus Assays 审中-公开
公开(公告)号：US20190025305A1
公开(公告)日：2019-01-24
申请号：US15838046
申请日：2017-12-11
申请人： Monogram Biosciences, Inc.
发明人： Douglas Richman , Mary T. Wrin , Susan Little , Christos J. Petropoulos , Neil T. Parkin , Jeannette Whitcomb , Wei Huang
IPC分类号： G01N33/569 , C12Q1/6897 , G01N33/50 , C12Q1/70 , C07K14/005 , C07K16/10 , C07K14/16 , C07K16/08
摘要： The present invention provides a method for identifying whether a compound inhibits entry of a virus into a cell which comprises: (a) obtaining nucleic acid encoding a viral envelope protein from a patient infected by the virus; (b) co-transfecting into a first cell (i) the nucleic acid of step (a), and (ii) a viral expression vector which lacks a nucleic acid encoding an envelope protein, and which comprises an indicator nucleic acid which produces a detectable signal, such that the first cell produces viral particles comprising the envelope protein encoded by the nucleic acid obtained from the patient; (c) contacting the viral particles produced in step (b) with a second cell in the presence of the compound, wherein the second cell expresses a cell surface receptor to which the virus binds; (d) measuring the amount of signal produced by the second cell in order to determine the infectivity of the viral particles; and (e) comparing the amount of signal measured in step (d) with the amount of signal produced in the absence of the compound, wherein a reduced amount of signal measured in the presence of the compound indicates that the compound inhibits entry of the virus into the second cell.

8. 发明授权

US10161931B2 Methods for determining susceptibility to coreceptor inhibitors 有权
公开(公告)号：US10161931B2
公开(公告)日：2018-12-25
申请号：US15348307
申请日：2016-11-10
申请人： Monogram Biosciences, Inc.
发明人： Wei Huang
IPC分类号： C12Q1/70 , A61K39/395 , A61K38/00 , A61K39/21 , C07K14/435 , G01N33/50 , C12Q1/6897 , G01N33/68
摘要： The invention provides a method for determining whether a human immunodeficiency virus is likely to be have enhanced ability to enter a cell expressing CD4 and CXCR4 relative to a reference HIV. In certain aspects, the methods comprise detecting one or more amino acids in an envelope protein of the HIV associated with enhanced ability to enter CD4- and CXCR4-expressing cells and determining that the HIV's ability to enter such cells is enhanced relative to a reference HIV, e.g., an HIV that does not comprise such amino acid(s).

9. 发明申请

US20200216919A1 METHODS FOR DETERMINING RESISTANCE OR SUSCEPTIBILITY TO HIV ENTRY INHIBITORS 审中-公开
公开(公告)号：US20200216919A1
公开(公告)日：2020-07-09
申请号：US16544838
申请日：2019-08-19
申请人： Monogram Biosciences, Inc.
发明人： Wei Huang
IPC分类号： C12Q1/70
摘要： The invention provides a method for determining whether a human immunodeficiency virus is likely to be more resistant to a viral entry inhibitor than a reference HIV. In certain aspects, the methods comprise comparing the length of one or more variable regions of an envelope protein of the HIV or a number of glycosylation sites on the envelope protein of the HIV to a length of one or more corresponding variable regions of an envelope protein of the reference HIV or a number of glycosylation sites on the envelope protein of the reference HIV, wherein the HIV is likely to be more resistant to the CD4 binding site entry inhibitor than the reference HIV when the HIV has longer variable regions than the reference HIV or the HIV has more glycosylation sites than the reference HIV.

10. 发明授权

US10385411B2 Methods for determining resistance or susceptibility to HIV entry inhibitors 有权
公开(公告)号：US10385411B2
公开(公告)日：2019-08-20
申请号：US15362141
申请日：2016-11-28
申请人： Monogram Biosciences, Inc.
发明人： Wei Huang
IPC分类号： C12Q1/70
摘要： The invention provides a method for determining whether a human immunodeficiency virus is likely to be more resistant to a viral entry inhibitor than a reference HIV. In certain aspects, the methods comprise comparing the length of one or more variable regions of an envelope protein of the HIV or a number of glycosylation sites on the envelope protein of the HIV to a length of one or more corresponding variable regions of an envelope protein of the reference HIV or a number of glycosylation sites on the envelope protein of the reference HIV, wherein the HIV is likely to be more resistant to the CD4 binding site entry inhibitor than the reference HIV when the HIV has longer variable regions than the reference HIV or the HIV has more glycosylation sites than the reference HIV.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式